Effects of Beta Amyloid on the DNA Methylation Status of an in Vitro Model of Alzheimer’s Disease

Available evidence points toward an epigenetic process in Alzheimer’s disease. This thesis describes the research that was done to investigate changes in DNA methylation using an in vitro model of the disease. Although the results indicated no global changes in methylation levels after treating differentiated IMR-32 cells with beta amyloid, there were several regions of the genome that changed their methylation status. Gene ontology studies revealed that these regions are associated with neuronal differentiation and cell fate genes, thus providing a possible model for the contribution of beta amyloid to the development of Alzheimer’s disease. This study provides incentive to further study the epigenetic processes in Alzheimer’s disease and explore avenues to reverse such epigenetic changes

Aβ Alters the DNA Methylation Status of Cell-fate Genes in an Alzheimer’s Disease Model

Alzheimer’s disease (AD) is characterized by neurofibrillary tangles and extracellular amyloid-β plaques (Aβ). Despite ongoing research, some ambiguity remains surrounding the role of Aβ in the pathogenesis of this neurodegenerative disease. While several studies have focused on the mutations associated with AD, our understanding of the epigenetic contributions to the disease remains less clear. To that end, we determined the changes in DNA methylation in differentiated human neurons with and without Aβ treatment. We isolated the DNA from neurons treated with Aβ or vehicle, and digested the two samples with either a methylation-sensitive (HpaII) or a methylation-insensitive (MspI) restriction endonuclease. The fragments were amplified and co- hybridized to a commercial promoter microarray. Data analysis revealed a subset of genomic loci that shows a significant change in DNA methylation following Aβ treatment in comparison to the control group. After mapping these loci to nearby genes, we discovered high enrichment for cell-fate genes that control apoptosis and neuronal differentiation. Finally, we incorporated three of those genes in a possible model suggesting the means by which Aβ contributes to the brain shrinkage and memory loss seen in AD

Molecular characterization of firefly nuptial gifts: a multi-omics approach sheds light on postcopulatory sexual selection

Postcopulatory sexual selection is recognized as a key driver of reproductive trait evolution, including the machinery required to produce endogenous nuptial gifts. Despite the importance of such gifts, the molecular composition of the non-gametic components of male ejaculates and their interactions with female reproductive tracts remain poorly understood. During mating, male Photinus fireflies transfer to females a spermatophore gift manufactured by multiple reproductive glands. Here we combined transcriptomics of both male and female reproductive glands with proteomics and metabolomics to better understand the synthesis, composition and fate of the spermatophore in the common Eastern firefly, Photinus pyralis. Our transcriptome of male glands revealed up-regulation of proteases that may enhance male fertilization success and activate female immune response. Using bottom-up proteomics we identified 208 functionally annotated proteins that males transfer to the female in their spermatophore. Targeted metabolomic analysis also provided the first evidence that Photinus nuptial gifts contain lucibufagin, a firefly defensive toxin. The reproductive tracts of female fireflies showed increased gene expression for several proteases that may be involved in egg production. This study offers new insights into the molecular composition of male spermatophores, and extends our understanding of how nuptial gifts may mediate postcopulatory interactions between the sexes.Tuft University. Faculty Research Fund (FRAC (S.M.L.)Arnold and Mabel Beckman Foundation. Beckman Young InvestigatorPew Scholars Program in the Biomedical SciencesSearle Scholars Progra

The Year in Cardiology 2013: heart failure

Heart failure has become a worldwide epidemic of the 21st century with increasing impact on healthcare systems. The 2012 ESC and 2013 ACCF/AHA guidelines have set the stage for current therapy to reduce mortality and morbidity. There is a dawn of hope for therapy of acute and diastolic heart failure; it has become clearer that patients benefit from mitral reconstruction and which patients benefit from heart failure management programmes; genetics and proteomics advance in great strides; competing concepts of cell therapy seem to spiral, hopefully upwards; and we can further nurture our hope for evidence-based individualized diagnostic and therap

Analyzing marker substances for Complex Regional Pain Syndrome (CRPS)

Weniger als 5% der Patienten entwickeln Komplex-Regionales Schmerzsyndrom (CRPS) nach einem Trauma, insbesondere nach Frakturen. Es ist ein schmerzhaftes Syndrom, dass durch eine Vielzahl von klinischen Merkmalen gekennzeichnet ist. Es kann chronisch werden, wenn es nicht in den ersten Monaten kuriert wird. Wahrscheinlich spielen mehrere pathophysiologische Mechanismen eine Rolle in CRPS. Es wird vermutet, dass Neuropeptide und anti-inflammatorische Lipid-Mediatoren involviert sind. In dieser Arbeit wurden diese Moleküle in Hautbiopsien und Serum mit dem Ziel der Korrelation ihrer Konzentration mit klinischen Parametern mittels Massenspektrometrie (MS) untersucht. Hochauflösende und insbesondere NanoMS identifizierte Peptide und Fettsäuren im niederen fmol-Bereich. Die Methodik zeigte aber auch wenig Toleranz gegenüber dem chemischen Untergrund, so dass vornehmlich die robustere Kapillarchromatography eingesetzt wurde. Die Serum-Proteaseaktivität mit einem Fokus auf Angiotensin-konvertierendem Enzym (ACE) wurde untersucht. Bradykinin (BK) wurde zügig zu BK1-8 und BK1-5 abgebaut. Niedrigere BK1-5 Levels waren in Übereinstimmung mit der Hypothese verringerter ACE-Aktivität in CRPS.Less than 5% of patients develop Complex Regional Pain Syndrome (CRPS) after trauma, mostly after fractures. It is a painful syndrome characterized by a variety of clinical features including classical signs of inflammation and it can become chronical if not cured in the first few months. Likely, a number of pathophysiological mechanisms play a role in CRPS. The involvement of neuropeptides and anti-inflammatory lipid mediators has been suggested. Here, mass spectrometry (MS) was used to investigate these molecules in skin biopsies and serum with the aim of correlating their concentration with clinical parameters. High-end and in particular nanoscale MS identified peptides as well as fatty acids at the low fmol level. However, it also showed little tolerance for the chemical background so that a more robust capillary chromatography approach was preferentially used. Serum protease activity with a focus on angiotensin converting enzyme (ACE) was studied. Bradykinin (BK) was rapidly degraded to BK1-8 and BK1-5. The formation of lower BK1-5 levels was indicated in agreement with the hypothesis of reduced ACE-activity in CRPS

Epigenetic modifications of chronic hypoxia-mediated neurodegeneration in Alzheimer’s disease

Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting the elderly people. AD is characterized by progressive and gradual decline in cognitive function and memory loss. While familial early-onset AD is usually associated with gene mutations, the etiology of sporadic late-onset form of AD is largely unknown. It has been reported that environmental factors and epigenetic alterations significantly contribute to the process of AD. Our previous studies have documented that chronic hypoxia is one of the environmental factors that may trigger the AD development and aggravate the disease progression. In this review, we will summarize the pathological effects of chronic hypoxia on the onset and development of AD and put forward the possible molecule mechanisms underlying the chronic hypoxia mediated AD pathogenesis. Finally, we propose that epigenetic regulations may represent new opportunity for the therapeutic intervention of this disease

Functional amyloid formation in LPS activated cells from invertebrates to vertebrates

LPS stimulation provokes serious cellular stress with an increase of cytoplasmic reactive oxygen species (ROS). We have investigated, among the different cellular defenses, amyloidogenesis as common physiological response to attenuate oxidative stress. Optical and electron microscopic observations of the following LPS activated cell lines [insect (larval hemocytes, IPLB-LdFB and Drosophila Schneider\u2019s S2 cells); mouse (NIH3T3 embryonic fibroblasts); Human (Human Umbilical Vein Endothelial Cells (HUVEC), neutrophils, and mesenchymal stem cells] reveal that, all are characterized by irregular profiles, cytoplasmic empty vacuoles or by cisternae containing fibrillar material. The compartmentalized fibrillar material shows staining properties typical of amyloid fibrils. LPS activation leads to ROS generation, resulting in pH acidification. Stimulated cells show pink cytoplasm in May-Gr\ufcnwald Giemsa differential staining, giving a gross indication of a lower intracellular pH. Moreover the activation of amyloidogenesis is also linked with an extensive production of ACTH and \u3b1-MSH in all cultured cell types. We suggest that amyloidogenesis is a common, physiological cellular response to weak ROS, starting when other anti-stress cellular systems failed to restore homeostasis. The morphological evidence and/or functional characterization of synthesized amyloid fibrils could be an early indicator of oxidative stress that may lead to a general inflammatory process

The white-knight hypothesis, or does the environment limit innovations?

Organisms often harbor latent traits that are byproducts of other adaptations. Such latent traits are not themselves adaptive but can become adaptive in the right environment. Here I discuss several examples of such traits. Their abundance suggests that environmental change rather than new mutations might often limit the origin of evolutionary adaptations and innovations. This is important, because environments can change much faster than new mutations arise. I introduce a conceptual model that distinguishes between mutation-limited and environment-limited trait origins and suggest how experiments could help discriminate between them. Wherever latent traits are plentiful, ecology rather than genetics might determine how fast new adaptations originate and thus how fast adaptive Darwinian evolution proceeds

Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease

Alzheimer's disease and other age-related neurodegenerative disorders are associated with deterioration of the noradrenergic locus coeruleus (LC), a probable trigger for mood and memory dysfunction. LC noradrenergic neurons exhibit particularly high levels of somatostatin binding sites. This is noteworthy since cortical and hypothalamic somatostatin content is reduced in neurodegenerative pathologies. Yet a possible role of a somatostatin signal deficit in the maintenance of noradrenergic projections remains unknown. Here, we deployed tissue microarrays, immunohistochemistry, quantitative morphometry and mRNA profiling in a cohort of Alzheimer's and age-matched control brains in combination with genetic models of somatostatin receptor deficiency to establish causality between defunct somatostatin signalling and noradrenergic neurodegeneration. In Alzheimer's disease, we found significantly reduced somatostatin protein expression in the temporal cortex, with aberrant clustering and bulging of tyrosine hydroxylase-immunoreactive afferents. As such, somatostatin receptor 2 (SSTR2) mRNA was highly expressed in the human LC, with its levels significantly decreasing from Braak stages III/IV and onwards, i.e., a process preceding advanced Alzheimer's pathology. The loss of SSTR2 transcripts in the LC neurons appeared selective, since tyrosine hydroxylase, dopamine beta-hydroxylase, galanin or galanin receptor 3 mRNAs remained unchanged. We modeled these pathogenic changes in Sstr2 -/- mice and, unlike in Sstr1 -/- or Sstr4 -/- genotypes, they showed selective, global and progressive degeneration of their central noradrenergic projections. However, neuronal perikarya in the LC were found intact until late adulthood (<8 months) in Sstr2 -/- mice. In contrast, the noradrenergic neurons in the superior cervical ganglion lacked SSTR2 and, as expected, the sympathetic innervation of the head region did not show any signs of degeneration. Our results indicate that SSTR2-mediated signaling is integral to the maintenance of central noradrenergic projections at the system level, and that early loss of somatostatin receptor 2 function may be associated with the selective vulnerability of the noradrenergic system in Alzheimer's disease